Search - tctmd.com

Displaying 21 - 40 of 58

Sort: Relevancy | Date

News Opinion CV Team Dispatch

December 2023 Dispatch for the CV Team

L.A. McKeown

December 01, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

Todd Neale

October 11, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

Advertisement

December 2023 Dispatch for the CV Team

November 2023 News Roundup

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Dapagliflozin Boosts Health Status Across LVEF Range

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Guideline-Directed Therapies Underused in Frail HF Patients

March 2022 News Roundup

FDA Approves Empagliflozin for Treatment of HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content